Summit Core Lung Cancer Drug Rejected by FDA, Shares Plunge
Summit Therapeutics Inc. fell to a 52-week low on Monday after the U.S. Food and Drug Administration rejected the company's marketing application for its core cancer drug. On…
Summit Therapeutics Inc. fell to a 52-week low on Monday after the U.S. Food and Drug Administration rejected the company's marketing application for its core cancer drug.
On Sunday, the FDA issued a complete response letter, stating it could not approve the Biologics License Application for ivonescimab in its current form.
Summit sought approval for the novel PD-1 x VEGF bispecific antibody in combination with platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer in patients previously treated with epidermal growth factor receptor tyrosine kinase inhibitors.
FDA Cites Overall Survival Data
The regulator determined that Summit failed to establish sufficient evidence of efficacy in the absence of a statistically significant improvement in overall survival.
The FDA noted that progression-free survival benefit alone is insufficient to support a positive benefit-risk profile when there is no statistically significant improvement in overall survival.
The company noted that no FDA-approved regimen has demonstrated a statistically significant overall survival benefit in this treatment setting. While ivonescimab plus chemotherapy showed a positive overall survival trend in the primary analysis, it did not reach statistical significance.
However, a post-hoc analysis with longer follow-up in Western patients showed consistent overall survival benefits across regions, yielding a hazard ratio of 0.76 in the overall population, Asian patients, and Western patients.
HARMONi Trial and Safety Results
The BLA was supported by data from the Phase III HARMONi trial. The study evaluated ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer who had previously received a third-generation EGFR TKI.
The HARMONi trial met its primary endpoint of progression-free survival, becoming the first global Phase III immunotherapy study to demonstrate a statistically significant progression-free survival improvement in this treatment setting, supported by more mature Western patient data.
The combination therapy demonstrated an acceptable and manageable safety profile, consistent with prior studies, with no new safety signals and comparable discontinuation and mortality rates across treatment arms.
Global Regulatory Status
No regulatory agency has approved ivonescimab in Summit's licensed territories, including the United States and Europe, and no PD-1 x VEGF bispecific antibody is currently approved in the U.S.
China first approved ivonescimab in May 2024.
SMMT Stock Movement: Summit Therapeutics shares fell 17.31% in premarket trading on Monday to $11.70. The stock is trading at a new 52-week low.
insigtX content is informational and educational, not investment advice.